Results 31 to 40 of about 1,992 (155)

Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?

Frontiers in Psychiatry, 2022
Dopamine receptor partial agonists (DRPAs; aripiprazole, brexpiprazole, and cariprazine) constitute a novel class of antipsychotics. Although they share a similar mechanism of action, DRPAs differ in their pharmacodynamics, pharmacokinetics, drug ...
Pavel Mohr, Pavel Mohr, Jirí Masopust, Miloslav Kopeček, Miloslav Kopeček   +4 more
doaj   +1 more source

Successful high dose antipsychotic treatment with cariprazine in patients on the schizophrenia spectrum: Real-world evidence from a Spanish hospital setting

Frontiers in Psychiatry, 2023
Real-world evidence fills in an important gap by providing data on the effectiveness and tolerability of new medications in everyday patients. In this data collection form a Spanish hospital, the effectiveness and tolerability of cariprazine were ...
Lluis Niell Galmes, Elmars Rancans
doaj   +1 more source

Cariprazine as a strategy for augmentation of treatment of major depressive disorder: from pharmacological aspects to clinical practice

Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева
Major depressive disorder remains the leading cause of disability worldwide, with up to 33% of patients failing to respond to antidepressant therapy.
A. V. Kidyaeva, R. F. Nasyrova
doaj   +1 more source

Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment)

Drug Design, Development and Therapy, 2016
Tadakatsu Nakamura,1 Tomoko Kubota,1 Atsushi Iwakaji,1 Masayoshi Imada,1 Margit Kapás,2 Yasunori Morio1 1Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan; 2Developmental Drug Metabolism and ...
Nakamura T, Kubota T, Iwakaji A, Imada M, Kapás M, Morio Y   +5 more
doaj  

Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies

Neuropsychiatric Disease and Treatment, 2021
Ágota Barabássy,1 Barbara Sebe,1 Károly Acsai,1 István Laszlovszky,1 Balázs Szatmári,1 Willie R Earley,2 György Németh1 1Medical Division, Gedeon Richter Plc, Budapest, Hungary; 2Clinical Development,
Barabássy Á, Sebe B, Acsai K, Laszlovszky I, Szatmári B, Earley WR, Németh G   +6 more
doaj  

Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine

Drug Design, Development and Therapy, 2019
Béla Kiss, Zsolt Némethy, Károly Fazekas, Dalma Kurkó, István Gyertyán, Katalin Sághy, István Laszlovszky, Bence Farkas, Norbert Kirschner, Etelka Bolf-Terjéki, Ottilia Balázs, Bal ...
Kiss B, Némethy Z, Fazekas K, Kurkó D, Gyertyán I, Sághy K, Laszlovszky I, Farkas B, Kirschner N, Bolf-Terjéki E, Balázs O, Lendvai B   +11 more
doaj  

A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia

Therapeutics and Clinical Risk Management, 2013
Silvio Caccia, Roberto William Invernizzi, Alessandro Nobili, Luca Pasina IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy Abstract: Cariprazine is a potential antipsychotic awaiting approval from the US Food and Drug Administration ...
Caccia S, Invernizzi RW, Nobili A, Pasina L   +3 more
doaj  

Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis

BMC Psychiatry, 2021
Background While clinical trial evidence has firmly established the efficacy of several atypical antipsychotics (AAPs) for treating bipolar depression, no randomized controlled trials (RCT’s) comparing AAPs have been conducted. This Bayesian network meta-
Aditi Kadakia, Carole Dembek, Vincent Heller, Rajpal Singh, Jennifer Uyei, Katsuhiko Hagi, Tadashi Nosaka, Antony Loebel   +7 more
doaj   +1 more source

Efficacy and Tolerability of Cariprazine as Monotherapy for Acute Bipolar Depression: A Systematic Review and Meta-analysis

Journal of Psychiatry Spectrum
Background: Bipolar depression (BDep) presents a significant clinical challenge with limited treatment options. The second-generation antipsychotics are increasingly utilized as primary or adjunct treatments.
Poulami Laha, Rakshathi Basavaraju, Soumya Parameshwaran, Dinakaran Damodaran, Palash Kumar Malo, Binukumar Bhaskarapillai, Muralidharan Kesavan   +6 more
doaj   +1 more source

From Antipsychotic to Antitumor Agent: Cariprazine Suppresses Glioblastoma via D2/D3-ARRB2 Axis Modulation

Pharmaceuticals
Background: Glioblastoma (GBM) is among the malignant tumors with the lowest five-year survival rate. Current treatments offer limited efficacy and first-line options are scarce, highlighting the urgent need for novel drugs.
Haotian Zhang, Haowei Liu, Jiangpeng Xu, Xiaoling Li, Shasha Li, Xuemei Liu, Changhua Hu   +6 more
doaj   +1 more source